US Pharma MarketingHow GSK
SEC filings reveal how GSK Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and…
Luke Miels made plans for a big cancer deal to grow GSK's small oncology portfolio before he began as CEO at the start of this year.
The $10.6 billion buyout of Nuvalent ...
Source: Endpoints News